✦ LIBER ✦

6075 A triple combination of Imatinib, Bevacizumab and Cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer

✍ Scribed by Pessino, A.; Andretta, V.; Guglielmi, A.; Mammoliti, S.; Caprioni, F.; Fornarini, G.; Comandini, D.; Sciallero, S.; Ansaldi, F.; Sobrero, A.

Book ID: 122487530
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71170-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase 1B Study of Dulanermin in Combin

A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

✍ Wainberg, Zev A.; Messersmith, Wells A.; Peddi, Parvin F.; Kapp, Amy V.; Ashkena 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 608 KB

Phase II study and biomarker analysis of

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

✍ Han, S-W; Oh, D-Y; Im, S-A; Park, S R; Lee, K-W; Song, H S; Lee, N-S; Lee, K H; 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 148 KB

A phase I trial of imatinib in combinati

A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer

✍ M. Michael, J. Zalcberg, P. Gibbs, L. Lipton… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 251 KB

Efficacy and safety of bevacizumab-based

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)

✍ Ducreux, M.; Adenis, A.; Pignon, J.-P.; François, E.; Chauffert, B.; Ichanté, J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 602 KB

PEAK: A Randomized, Multicenter Phase II

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

✍ Schwartzberg, L. S.; Rivera, F.; Karthaus, M.; Fasola, G.; Canon, J.-L.; Hecht, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 520 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

✍ Bendell, Johanna C.; Ervin, Thomas J.; Gallinson, David; Singh, Jaswinder; Walla 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 608 KB